Why COVID-19 patients who could most benefit from Paxlovid still aren’t getting it
American Nurse
MARCH 13, 2024
A recent JAMA Network study found that sick people 85 and older were less likely than younger Medicare patients to get covid therapies like Paxlovid. The drug might have prevented up to 27,000 deaths in 2022 if it had been allocated based on which patients were at highest risk from covid. government 23.7 Pfizer reported $12.5
Let's personalize your content